Drug Trial Radar · NCT06653842
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Dec 20, 2024
Primary completion
Nov 21, 2025
Study completion Mar 2026
Sponsor
- Lead sponsor
- Palvella Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Conditions
- Cutaneous Venous Malformations
Interventions
QTORIN 3.9% rapamycin anhydrous gelDrug
QTORIN 3.9% Rapamycin Anhydrous Gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: Week 12
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital of Orange County
Irvine, California
Stanford University
Palo Alto, California
Colorado Children's Hospital
Aurora, Colorado
Johns Hopkins
Baltimore, Maryland
Minnesota Clinical Study Center
New Brighton, Minnesota
Mayo Clinic
Rochester, Minnesota
University of North Carolina
Chapel Hill, North Carolina
Cleveland Clinic
Cleveland, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
University of Utah Health
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.